The drug is also being investigated in clinical trials as a chemotherapeutic agent for various cancers.101 A nonretinoid RBP‐4 antagonist, A1120, was shown to decrease serum RBP‐4 levels by 75% in mice.102. This evidence concerns the gene RBP4 and cancer.